Summary
In order to investigate the possible impact of chronic renal insufficiency on the pharmacokinetic and pharmacodynamic properties of bunazosin, 3mg of this novel α 1-adrenoceptor antagonist were administered once daily for 2 weeks to 24 patients with hypertension. 12 of the patients had normal renal function (controls) while 12 others suffered from chronic renal insufficiency.
The mean area under the plasma concentration-time curve in patients with renal insufficiency on day 1 (AUC0–48) was 142 ± 65.0 ng/ml • h and rose to 242 ± 204.0 ng/ml • h on day 15. In controls, corresponding values were significantly lower (57 ± 42.9 and 95.5 ± 48.9 ng/ml • h, respectively). Plasma clearance of bunazosin was also reduced in renally impaired patients (193 ± 103 ml/min) compared with controls (623 ± 484 ml/min). Stroke volume and cardiac output increased in both groups and returned to baseline values within 24 hours of bunazosin administration. Blood pressure was markedly reduced from baseline values in both groups to a similar extent. The duration of antihypertensive activity lasted at least 12 hours and no loss of activity was observed during the course of treatment. In both groups, a close correlation between plasma concentrations and haemodynamic effects of bunazosin could be demonstrated.
Similar content being viewed by others
References
Ahmed JH, Elliot HC, Grant AC, Rodger RSC, Reid JL. The pharmacokinetics and pharmacodynamics of nicardipine in patients with renal impairment. British Journal of Clinical Pharmacology 29: 145–146, 1990
Ankermann T, Osterkamp U, Santso SR, Kirch W. Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure. European Journal of Clinical Pharmacology 36: 433–437, 1989
Baba T, Tomiyama T, Murabayashi S, Takebe K. Renal effects of bunazosin, a new alpha-1-adrenoceptor blocker, in patients with mild-to-moderate essential hypertension. Journal of Cardiovascular Pharmacology 15: 826–830, 1990
Carlson RV, Bailey RR, Begg W, Colishaw MG, Sharman JR. Pharmacokinetics and effect on blood pressure of doxazosin in normal subjects and patients with renal failure. Clinical Pharmacology and Therapeutics 40: 561–566, 1986
Dylewicz P, Kirch W, Santos SR, Hutt HJ, Mönig H, et al. Bioavailability and elimination of nitrendipine in liver disease. European Journal of Clinical Pharmacology 32: 563–568, 1987
Evans JM, Skidmore R, Baker JD, Wells PNT. A new approach to the non-invasive measurement of cardiac output using an annular array technique. II: Practical implementation and results. Ultrasound in Medicine and Biology 15: 179–187, 1989b
Evans JM, Skidmore R, Luckman NP, Wells PNT. A new approach to the non-invasive measurement of cardiac output using an annular array Doppler technique. I: Theoretical considerations and ultrasonic field. Ultrasound in Medicine and Biology 15: 169–178, 1989a
Halabi A, Endell W, Halabi I, Kirch W. Hemodynamic effects of brefanolol and propranolol assessed by noninvasive methods in patients with arterial hypertension. Journal of Cardiovascular Pharmacology 16: 81–86, 1990a
Halabi A, Linde M, Saathoff H, Nokhodian A, Dylewicz P, et al. Hemodynamic effects of diltiazem and nitrendipine assessed by noninvasive methods in patients with congestive heart failure. American Journal of Noninvasive Cardiology 4: 60–64, 1990b
Hata F, Kondo S, Kagawa K, Ishida H. Characteristics of (3H)E-643-binding to alpha adrenoceptors. Japanese Journal of Pharmacology 32: 181–187, 1982
Helger R, Rindfrey H, Hilgenfeldt J. Eine Methode zur direkten Bestimmung des Kreatinins in Serum und Harn ohne Enteiweiβung nach einer modifizierten Jaffé-Methode. Zeitschrift für Klinische Chemie und Klinische Biochemie 12: 344–349, 1974
Hirata Y, Fukui K, Matsuoka H, Sugimoto T, Ishii M. Renal and hormonal effects of α1-adrenoceptor blockade by bunazosin in essential hypertension. European Journal of Clinical Pharmacology 36: 575–578, 1989
Hottinger CF, Meindl JD. Blood flow measurement using the attenuation compensated volume flowmeter. Ultrasonic Imaging 1: 1–15, 1979
Jungers P, Ganeval D, Pertuiset N, Chaveau P. Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin. American Journal of Medicine 80(Suppl. 5B): 94–99, 1986
Kawahara Y, Hasegawa K, Sawayama T, Inoue S, Nakamua T, et al. The effect of bunazosin versus captopril on hemodynamic and neurohumoral parameters in patients with congestive heart failure. Kokyu to Junkan 3: 1333–1340, 1989
Kawasaki T, Uezono K, Abe I, Nakamuta S, Ueno M, et al. Antihypertensive effect of E-643, a new alpha-adrenergic blocking agent. European Journal of Clinical Pharmacology 20: 399–405, 1981
Kirch W, Halabi A, Hinrichsen H. Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. Clinical Pharmacology and Therapeutics 51: 325–333, 1992
Kirch W, Hutt HJ, Heidemann H, Rämsch K, Janisch HD, et al. Drug interactions with nitrendipine. Journal of Cardiovascular Pharmacology 6: S982–S985, 1984a
Kirch W, Rämsch KD, Dührsen U, Ohnhaus EE. Clinical pharmacokinetics of nimodipine in normal and impaired renal function. International Journal of Clinical Pharmacology Research 4: 381–384, 1984b
Köhler H, Kirch W, Höffler D. Pharmakokinetik und Dosierung von Dextran 40 in Abhängigkeit von der Nierenfunktion. Klinische Wochenschrift 52: 1111–1114, 1974
Lameire N, Gordts J. A pharmacokinetic study of prazosin in patients with varying degrees of chronic renal failure. European Journal of Clinical Pharmacology 31: 333–337, 1986
Lowenthal DT, Briggs WA, Gibson TP, Nelson H, Cirkensas J. Pharmacokinetics of oral propranolol in chronic renal disease. Clinical Pharmacology and Therapeutics 16: 761–769, 1974
Nakano A, Tamura T, Hatori M, Hasegawa A, Suzuki T, et al. Exercise testing of the chronic effects of bunazosin hydrochloride on dilated cardiomyopathy. Arzneimittel-Forschung 39: 1590–1592, 1989
Nokhodian A, Halabi A, Kirch W. Plasma levels, elimination and blood pressure values on bunazosine treatment in patients with normal or impaired hepatic and renal function. Abstract. Journal of Clinical Pharmacology 31: 850, 1991
Oishi S, Sasaki M, Ohno M, Umeda T, Sato T. Periodic fluctuation of blood pressure and its management in a patient with pheochromocytoma. Case report and review of the literature. Japanese Heart Journal 29: 389–399, 1988
Shoji T. Comparison of pre- and postsynaptic alpha-adrenoceptor blocking effects of E-643 in the isolated vas deferens of the rat. Japanese Journal of Pharmacology 31: 361–368, 1981
Shoji T, Daiku Y, Igarashi T. Alpha-adrenoceptor blocking properties of a new antihypertensive agent, 2-(4-(n-butyryl)-homopiperazine-1-y1)-4-amino-6,7-dimethoxyquinazoline (E-643). Japanese Journal of Pharmacology 30: 763–772, 1980
Silke B, Verma SD, Taylor H. Pharmacodynamic monitoring during acute intervention in ischaemic heart disease using a new echo-doppler device. British Journal of Clinical Pharmacology 29: 741–747, 1990
Somberg JC, Achari R, Laddu AR. Terazosin: Pharmacokinetics and the effect of age and dose on the incidence of adverse events. American Heart Journal 122: 901–905, 1991
Soons PA, Ankermann T, Breimer DD, Kirch W. Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function. European Journal of Clinical Pharmacology 42: 423–427, 1992
Takimoto Y, Kitamura K, Fuse T, Kawazoe K, Hirano D, et al. Clinical effect of a new alpha-adrenergic blocker on micturition disturbance of neurogenic bladder and lower urinary tract obstruction. Hinyokika Kiyo 29: 255–263, 1983
Wagner JG. Fundamentals of clinical pharmacokinetics, p. 71. Drug Intelligence Publications, Hamilton, IL, 1975
Yamamoto M, Takaba H, Hashimoto J, Miyake K, Fujita T. Successful treatment of oligospermic and azoospermic men with alpha-1-blocker and beta-stimulator: new treatment for idiopathic male infertility. Fertility and Sterility 46: 1162–1164, 1986
Yamato C, Takahashi T, Kinoshita K, Fujita T. The metabolic fate of 4-amino-2-(butanoyl-hexhydro-1H-1,4-diazepin-1-y1)-6,7-dimethoxy-quinazoline HC1. Xenobiotica 12: 549–559, 1982
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mescheder, A., Halabi, A., Nokhodian, A. et al. Antihypertensive Activity, Cardiac Performance and Pharmacokinetics of Bunazosin, a Novel α1-Adrenoceptor Antagonist, in Patients with Normal and Impaired Renal Function. Drug Invest 6, 263–270 (1993). https://doi.org/10.1007/BF03259597
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259597